Clinical Trial

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-18.
Trial Details
NCT Number NCT07315087
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, SLE-ITP
Enrollment 12 participants
Start Date 2026-01-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-01-18 (estimated)
Updated on ClinicalTrials.gov 2026-01-20